DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Brian Snyder - 1 Ali Mokdad - 1 Mokdad - 1 Irfan Khan - 1 Jennifer Kates - 1 Brad Pollock - 1 Nicole Iovine - 1 epidemiologist - 1
Top related locs:
U.S Covid Somerville , Massachusetts Novavax Eagle Rock , California Union Massachusetts
Top related orgs:
Pfizer - 2 Moderna - 2 Walgreens - 1 Centers for Disease Control - 1 CDC - 1 University of Washington - 1 CVS Pharmacy - 1 Los Angeles Times - 1

Search resuls for: "Novavax haven't"


2 mentions found


☆ Covid vaccine rates in the U.S. are slumping — and it will be a challenge to boost them
  + stars: | 2023-11-30 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +10 min
In this article PFEMRNANVAX Follow your favorite stocks CREATE FREE ACCOUNTA sign advertises Covid vaccine shots at a Walgreens Pharmacy in Somerville, Massachusetts, on Aug. 14, 2023. Brian Snyder | ReutersThree years into the Covid-19 pandemic, few Americans are rolling up their sleeves to get a Covid vaccine. Experts and vaccine makers can agree that low Covid vaccination rates are concerning, even as cases of the virus dwindle from their pandemic highs. However, Iovine of the University of Florida doesn't believe combination shots will have a significant effect on Covid vaccination rates. If combination shots don't do the trick, it's unclear what else could boost Covid vaccination rates down the line.
Persons: Brian Snyder, Ali Mokdad, Mokdad, Irfan Khan, Jennifer Kates, Brad Pollock, Nicole Iovine, epidemiologist, Iovine, Michael Yee, Albert Bourla, Arpa Garay, Garay, John Trizzino, Trizzino, Jamey Mock, Andrew Pekosz, Jefferies, Yee, doesn't Organizations: Walgreens, Reuters, Pfizer, Moderna, Centers for Disease Control, CDC, University of Washington, CVS Pharmacy, Los Angeles Times, KFF, UC Davis Health's, University of Florida, Jefferies, Arpa, CNBC, Istock, Getty, Johns Hopkins Bloomberg School of Public Health Locations: Somerville , Massachusetts, U.S, Novavax, Covid, Eagle Rock , California
☆ Moderna shares rise on better Covid vaccine outlook despite sharp drop in sales
  + stars: | 2023-08-03 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +4 min
Shares of Moderna rose Thursday after the biotech company hiked its full-year outlook for its Covid vaccine, its only marketable product, despite reporting a quarterly loss and sharp drop in revenue. But Moderna hopes to end the sales slump on strong demand for its updated Covid vaccine targeting the omicron subvariant XBB.1.5. The forecast includes around $4 billion in previously announced Covid vaccine purchase agreements and $2 billion to $4 billion in "signed and anticipated" contracts in the U.S. and other markets. Pfizer on Tuesday warned that Covid shot sales in the commercial market are uncertain, adding that vaccination rates will help the company better predict sales for 2023 and beyond. ET, which will likely provide more updates on its upcoming Covid vaccine rollout and drug pipeline.
Persons: Novavax haven't, Mandy Cohen Organizations: Moderna, Pfizer, Novavax, Food and Drug Administration, NPR, Merck Locations: U.S, Union, Massachusetts, Covid
0 next >>
Total: 2